Your browser doesn't support javascript.
loading
New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.
Maitre, Elsa; Bertrand, Philippe; Maingonnat, Catherine; Viailly, Pierre-Julien; Wiber, Margaux; Naguib, Dina; Salaün, Véronique; Cornet, Edouard; Damaj, Gandhi; Sola, Brigitte; Jardin, Fabrice; Troussard, Xavier.
Afiliação
  • Maitre E; Normandie Univ, INSERM U1245, Université de Caen, Caen, France.
  • Bertrand P; Normandie Univ, INSERM U1245, Université de Rouen, Rouen, France.
  • Maingonnat C; Normandie Univ, INSERM U1245, Université de Rouen, Rouen, France.
  • Viailly PJ; Normandie Univ, INSERM U1245, Université de Rouen, Rouen, France.
  • Wiber M; Laboratoire d'hématologie, CHU Caen, Caen, France.
  • Naguib D; Laboratoire d'hématologie, CHU Caen, Caen, France.
  • Salaün V; Laboratoire d'hématologie, CHU Caen, Caen, France.
  • Cornet E; Normandie Univ, INSERM U1245, Université de Caen, Caen, France.
  • Damaj G; Laboratoire d'hématologie, CHU Caen, Caen, France.
  • Sola B; Normandie Univ, INSERM U1245, Université de Caen, Caen, France.
  • Jardin F; Institut d'Hématologie de Basse-Normandie, CHU Caen, Caen, France.
  • Troussard X; Normandie Univ, INSERM U1245, Université de Caen, Caen, France.
Oncotarget ; 9(48): 28866-28876, 2018 Jun 22.
Article em En | MEDLINE | ID: mdl-29989027
ABSTRACT
Classical hairy cell leukemia (HCL-c) is a rare lymphoid neoplasm. BRAFV600E mutation, detected in more than 80% of the cases, is described as a driver mutation, but additional genetic abnormalities appear to be necessary for the disease progression. For cases of HCL-c harboring a wild-type BRAF gene, the differential diagnosis of the variant form of HCL (HCL-v) or splenic diffuse red pulp lymphoma (SDRPL) is complex. We selected a panel of 21 relevant genes based on a literature review of whole exome sequencing studies (BRAF, MAP2K1, DUSP2, MAPK15, ARID1A, ARID1B, EZH2, KDM6A, CREBBP, TP53, CDKN1B, XPO1, KLF2, CXCR4, NOTH1, NOTCH2, MYD88, ANXA1, U2AF1, BCOR, and ABCA8). We analyzed 20 HCL-c and 4 HCL-v patients. The analysis of diagnostic samples mutations in BRAF (n = 18), KLF2 (n = 4), MAP2K1 (n = 3), KDM6A (n = 2), CDKN1B (n = 2), ARID1A (n = 2), CREBBP (n = 2) NOTCH1 (n = 1) and ARID1B (n = 1). BRAFV600E was found in 90% (18/20) of HCL-c patients. In HCL-c patients with BRAFV600E , other mutations were found in 33% (6/18) of cases. All 4 HCL-v patients had mutations in epigenetic regulatory genes KDM6A (n = 2), CREBBP (n = 1) or ARID1A (n = 1). The analysis of sequential samples (at diagnosis and relapse) from 5 patients (2 HCL-c and 3 HCL-v), showed the presence of 2 new subclonal mutations (BCORE1430X and XPO1E571K ) in one patient and variations of the mutated allele frequency in 2 other cases. In the HCL-v disease, we described new mutations targeting KDM6A that encode a lysine demethylase protein. This opens new perspectives for personalized medicine for this group of patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França